天阳科技：医药研发、肿瘤创新药属于与公司主业完全无关的领域，不存在业务协同性

Core Viewpoint - Tianyang Technology (300872) emphasizes its commitment to focusing on its core business and ensuring business synergy in its investment strategy, which aligns with the general logic of industrial investment among A-share listed companies [1] Group 1: Investment Strategy - The company maintains that its external investments will strictly adhere to the principles of focusing on its main business and achieving business synergy [1] - Investments in areas such as pharmaceutical research and innovative cancer drugs are deemed unrelated to the company's core business, indicating a lack of business synergy [1] - The company plans to continue concentrating on its financial technology core business and will only invest in targets that provide business synergy and support long-term development [1]